Creating a Culture of Respectful Care for Pregnant and Postpartum People with Substance Use Disorders

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Creating a Culture of Respectful Care for Pregnant and Postpartum People with Substance Use Disorders - 2021 CE

In this interactive session, we will explore key elements, implementation guidance, and metrics associated with the 2021 revision of the Alliance for Innovation in Maternal Health (AIM) Care of Pregnant and Postpartum People with Substance Use Disorders Patient Safety Bundle.

Presenter:
Dr. Daisy Goodman, DNP, MPH, CNM, CARN-AP

contact hours - 1 CH, 0.25 hours of pharmacology

Activity ID# 21095173

Please fill out the post-test and survey to the best of your ability. You should expect your CE Certificate through email.

First Name *

Last Name *

Discipline *

MD/DO

NP Student

Required

Which of the following describes you? *

FNU Alumni

FNU Current Student

FNU Faculty

FNU Preceptor

Other....

Required

Population based studies show that maternal opioid use disorder is associated with *

A - High rates of hepatitis C

B - Fetal anomalies

C - Placental abruption

D - Preterm labor

The 2016 CARA Act included revised language mandating a Plan of Safe Care for infants affected by prenatal substance exposure. Which of the following are true? *

A - A Plan of Safe Care is required for all infants exposed to substances antenatally.

B - The process by which the Plan of Safe Care will be implemented is consistent across all states.

C - Federal legislation requires that when an infant is exposed to substances prenatally, a report to child protection authorities should be made.

D - Individual states are required to determine the process through which the Plan of Safe Care will be implemented in that state.

Core elements of the 2021 AIM Patient Safety Bundle: Care of Pregnant and Postpartum People with Substance Use Disorders include: *

A - Readiness; Recognition and Prevention; Response; Reporting and Systems Learning; Respectful, Equitable and Supportive Care

B - Prevention; Recognition; Readiness; Reporting and System Learning; Respectful Care

C - Readiness; Prevention; Response; Reflection; Respectful, Equitable, and Supportive Care

The 2021 AIM Patient Safety Bundle recommends the following approach for identifying the need for intervention for substance use among pregnant patients: *

A - Universal biological testing of all pregnant people (urine drug tests) at onset of prenatal care and at delivery

B - Biological testing (urine drug tests) for pregnant people presenting with high risk obstetric conditions such as placental abruption or preterm labor

C - Universal screening of all pregnant people for substance use, using validated, self-reported screening tools during prenatal care and at delivery

D - Screening all pregnant people with social or medical risk factors for substance use

Research supports the use of the following medications for the treatment of opioid use disorder during pregnancy and lactation: *

A - Buprenorphine

B - Naltrexone

C - Methadone

D - Disulfiram

E - Both A & C

Which of the following is true? *

A - The American College of Obstetricians and Gynecologists recommends that a pregnant person be administered naloxone in the event of an opioid overdose.

B - Administering naloxone to a person with physiologic dependence on opioids may cause abrupt withdrawal symptoms.

C - Naloxone is contraindicated in pregnancy.

D - There is insufficient evidence to determine whether naloxone should be administered to a pregnant person in the event of an opioid overdose.

E - Both A & B

Please complete the following sentence: “A pregnant person ________ (has/does not have) the right to refuse unwanted medical treatment, including drug and alcohol testing or screening.” *

A - Has

B - Does not have

The proportion of pregnant people with opioid use disorder (OUD) who receive medication for OUD (MOUD) is calculated each year by a hospital implementing the AIM SUD bundle. This metric is defined as: *

A - The number of pregnant people with OUD who receive MOUD divided by the total number of pregnant people with OUD delivering that year.

B - The number of pregnant people with OUD who receive MOUD divided by the total number of pregnant people delivering that year.

C - The number of pregnant people with OUD divided by the total number of pregnant people delivering that year.

D - The number of pregnant people with OUD divided by the number of pregnant people with OUD who received MOUD delivering that year.

True or false: According to national PRAMS data, all pregnant people are equally likely to be screened for substance use. *

A - True

B - False

Which of the following is true with regards to opioid overdose during pregnancy and the postpartum year? *

A - Opioid overdose is increasingly recognized as a cause of pregnancy-associated death in the United States.

B - Population based research suggests that opioid overdose is more common during the postpartum year than it is during pregnancy.

C - The physiologic changes of pregnancy increase metabolism of opioids, often necessitating dose increases of methadone or buprenorphine during to avoid withdrawal symptoms during pregnancy.

D - All of the above are true

As a result of my participation in this activity, I am better able to explore the impact of perinatal substance use on pregnant people, infants, families and communities, and identify opportunities to improve care for this vulnerable population. *

Strongly Agree

Strongly Disagree

As a result of my participation in this activity, I am better able to summarize core elements of the 2021 AIM Patient Safety Bundle: Care of Pregnant and Postpartum People with Substance Use Disorders. *

Strongly Agree

Strongly Disagree

As a result of my participation in this activity, I am better able to describe implementation strategies to promote evidence-based and respectful care for pregnant and postpartum people with substance use disorders. *

Strongly Agree

Strongly Disagree

As a result of my participation in this activity, I am better able to discuss metrics designed to evaluate the implementation of this Patient Safety Bundle. *

Strongly Agree

Strongly Disagree

Dr. Goodman demonstrated experiential knowledge of the topic? *

Strongly Agree

Strongly Disagree

Dr. Goodman fully disclosed any conflict of interest and discussion of off-label usage of medication and/or medical devices at the beginning of, or during the presentation? *

Strongly Agree

Strongly Disagree

Dr. Goodman's objectives/content topics were cohesive with one another? *

Strongly Agree

Strongly Disagree

The content provided fair and balanced coverage of the topic? *

Strongly Agree

Strongly Disagree

The content was free of commercial bias? *

Strongly Agree

Strongly Disagree

This activity enhanced my current knowledge base? *

Strongly Agree

Strongly Disagree

I would recommend this activity to my colleagues? *

Strongly Agree

Strongly Disagree

Additional Comments or Feedback:

Submit

Clear form

Never submit passwords through Google Forms.

This form was created inside of Frontier Nursing University.

Does this form look suspicious? Report

Forms